Last updated on February 2020

Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma


Brief description of study

A Phase 3b Proof-of-Concept study to evaluate the ability of fevipiprant dose 1 and dose 2, compared with placebo, as add-on to nasal spray standard-of-care (SoC), in reducing endoscopic nasal polyp score in adult ( 18 years) patients with nasal polyposis and concomitant asthma.

Clinical Study Identifier: NCT03681093

Find a site near you

Start Over

Novartis Investigative Site

Pasadena, CA United States
  Connect »

Novartis Investigative Site

Sacramento, CA United States
  Connect »

Novartis Investigative Site

Baltimore, MD United States
  Connect »

Novartis Investigative Site

San Miguel de Tucuman, Argentina
  Connect »

Novartis Investigative Site

Strzelce Opolskie, Poland
  Connect »